Drug intelligence / Profile preview

NVK033

Development stage: Unknown
Lead developer: Vyluma
Modality: Small Molecules
Administration: Topical

Overview

**NVK033** is a novel topical ophthalmic eye drop formulation developed by Vyluma for the treatment of hyperopia (farsightedness). It temporarily improves near vision while preserving distance vision and reducing associated symptoms such as eye strain and headaches, potentially as a first-in-class pharmacological therapy for this refractive error. The mechanism of action is not publicly detailed but is designed for proof-of-principle clinical evaluation in hyperopia patients.[1][3][11]

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on NVK033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVK033.

Explore the full profile